The N=1 Collaborative: advancing customized nucleic acid therapies through collaboration and data sharing.

Area of Science:

• Biotechnology
• Genetics
• Pharmacology

Background:

• Ultra-rare diseases affect millions globally, necessitating innovative therapeutic and regulatory approaches.
• Personalized medicine advancements are driving progress in nucleic acid therapies, including dosing, safety, and efficacy.
• The N=1 Collaborative (N1C) was formed to unite stakeholders in creating a shared ecosystem for personalized medicines.

Purpose of the Study:

• To review the current scientific and clinical ecosystems for customized genetic therapies.
• To explore necessary innovations, frameworks, and systems for delivering individualized medicines.
• To examine the progress and future directions of antisense oligonucleotide (ASO) development.

Main Methods:

• Convened leaders in scientific, regulatory, and advocacy fields for an inaugural meeting on ASO development in October 2024.
• Examined the existing landscape of personalized medicine development.
• Synthesized insights on enabling safe and scalable delivery of gene-targeting therapies.

Main Results:

• The N1C focuses initially on antisense oligonucleotides (ASOs) for rare, fatal neurodegenerative conditions.
• The collaborative aims to extend its frameworks to other treatment modalities and diseases.
• Progress in personalized therapies offers critical insights into nucleic acid treatments.

Conclusions:

• Developing customized gene-targeting therapies requires significant therapeutic and regulatory innovation.
• An open, shared ecosystem is crucial for advancing personalized medicines.
• Frameworks are needed to deliver individualized medicines safely and at scale.